SEPN
Septerna, Inc.
+1.37 (+3.56%)39.81USD101K成交股數1.9B市值–本益比(近四季)18.8股價營收比+22375.6%營收年增(近四季)2026-11-09下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 32 · 364M · 14 |
| 其中 10b5-1 計畫賣出 | 22 筆 |
| 近 180 天 買進 · 賣出金額 | 0 · 365M |
| 近 180 天 淨額 | −365M |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-01 | 09-03 | Long Daniel D. | SVP, Drug Discovery | M 選擇權執行 | 3.3K | 2.76 | 9K | 99.7K | SEC |
| 2026-09-01 | 09-03 | Long Daniel D. | SVP, Drug Discovery | S 公開市場賣出(10b5-1) | 3.3K | 37.83 | 126K | 96.4K | SEC |
| 2026-08-12 | 08-14 | RA Capital Healthcare Fund LP | Director,TenPercentOwner | S 公開市場賣出 | 747K | 42.50 | 31.7M | 4.8M | SEC |
| 2026-08-12 | 08-14 | RA Capital Healthcare Fund LP | Director,TenPercentOwner | S 公開市場賣出 | 747K | 42.50 | 31.7M | 725K | SEC |
| 2026-08-12 | 08-14 | RA CAPITAL MANAGEMENT, L.P. | Director,TenPercentOwner | S 公開市場賣出 | 747K | 42.50 | 31.7M | 4.8M | SEC |
| 2026-08-12 | 08-14 | RA CAPITAL MANAGEMENT, L.P. | Director,TenPercentOwner | S 公開市場賣出 | 747K | 42.50 | 31.7M | 725K | SEC |
| 2026-08-12 | 08-14 | Kolchinsky Peter | Director,TenPercentOwner | S 公開市場賣出 | 747K | 42.50 | 31.7M | 4.8M | SEC |
| 2026-08-12 | 08-14 | Kolchinsky Peter | Director,TenPercentOwner | S 公開市場賣出 | 747K | 42.50 | 31.7M | 725K | SEC |
| 2026-08-12 | 08-14 | Shah Rajeev M. | Director,TenPercentOwner | S 公開市場賣出 | 747K | 42.50 | 31.7M | 4.8M | SEC |
| 2026-08-12 | 08-14 | Shah Rajeev M. | Director,TenPercentOwner | S 公開市場賣出 | 747K | 42.50 | 31.7M | 725K | SEC |
| 2026-08-12 | 08-14 | RA Capital Nexus Fund III, L.P. | Director | S 公開市場賣出 | 747K | 42.50 | 31.7M | 4.8M | SEC |
| 2026-08-12 | 08-14 | RA Capital Nexus Fund III, L.P. | Director | S 公開市場賣出 | 747K | 42.50 | 31.7M | 725K | SEC |
| 2026-08-12 | 08-14 | Third Rock Ventures V, L.P. | TenPercentOwner | S 公開市場賣出(10b5-1) | 147K | 50.27 | 7.4M | 6.1M | SEC |
| 2026-08-12 | 08-14 | Third Rock Ventures V, L.P. | TenPercentOwner | S 公開市場賣出(10b5-1) | 141 | 51.08 | 7K | 6.1M | SEC |
| 2026-08-12 | 08-14 | Third Rock Ventures VI, L.P. | TenPercentOwner | S 公開市場賣出(10b5-1) | 147K | 50.27 | 7.4M | 6.1M | SEC |
| 2026-08-12 | 08-14 | Third Rock Ventures VI, L.P. | TenPercentOwner | S 公開市場賣出(10b5-1) | 141 | 51.08 | 7K | 6.1M | SEC |
| 2026-08-12 | 08-14 | Third Rock Ventures GP V, LP | TenPercentOwner | S 公開市場賣出(10b5-1) | 147K | 50.27 | 7.4M | 6.1M | SEC |
| 2026-08-12 | 08-14 | Third Rock Ventures GP V, LP | TenPercentOwner | S 公開市場賣出(10b5-1) | 141 | 51.08 | 7K | 6.1M | SEC |
| 2026-08-12 | 08-14 | Third Rock Ventures GP VI, L.P. | TenPercentOwner | S 公開市場賣出(10b5-1) | 147K | 50.27 | 7.4M | 6.1M | SEC |
| 2026-08-12 | 08-14 | Third Rock Ventures GP VI, L.P. | TenPercentOwner | S 公開市場賣出(10b5-1) | 141 | 51.08 | 7K | 6.1M | SEC |
| 2026-08-12 | 08-14 | TRV GP VI, LLC | TenPercentOwner | S 公開市場賣出(10b5-1) | 147K | 50.27 | 7.4M | 6.1M | SEC |
| 2026-08-12 | 08-14 | TRV GP VI, LLC | TenPercentOwner | S 公開市場賣出(10b5-1) | 141 | 51.08 | 7K | 6.1M | SEC |
| 2026-08-12 | 08-14 | TRV GP V, LLC | TenPercentOwner | S 公開市場賣出(10b5-1) | 147K | 50.27 | 7.4M | 6.1M | SEC |
| 2026-08-12 | 08-14 | TRV GP V, LLC | TenPercentOwner | S 公開市場賣出(10b5-1) | 141 | 51.08 | 7K | 6.1M | SEC |
| 2026-08-11 | 08-13 | Bhatt Elizabeth | President and COO | M 選擇權執行 | 18.7K | 6.81 | 127K | 193K | SEC |
| 2026-08-11 | 08-13 | Bhatt Elizabeth | President and COO | M 選擇權執行 | 6.3K | 2.76 | 17K | 199K | SEC |
| 2026-08-11 | 08-13 | Bhatt Elizabeth | President and COO | S 公開市場賣出(10b5-1) | 25.0K | 44.00 | 1.1M | 174K | SEC |
| 2026-08-03 | 08-05 | Long Daniel D. | SVP, Drug Discovery | M 選擇權執行 | 1.8K | 2.76 | 5K | 98.2K | SEC |
| 2026-08-03 | 08-05 | Long Daniel D. | SVP, Drug Discovery | M 選擇權執行 | 1.5K | 2.76 | 4K | 99.7K | SEC |
| 2026-08-03 | 08-05 | Long Daniel D. | SVP, Drug Discovery | S 公開市場賣出(10b5-1) | 1.0K | 33.98 | 34K | 98.7K | SEC |
| 2026-08-03 | 08-05 | Long Daniel D. | SVP, Drug Discovery | S 公開市場賣出(10b5-1) | 2.3K | 34.68 | 81K | 96.4K | SEC |
| 2026-07-15 | 07-17 | Bhatt Elizabeth | President and COO | M 選擇權執行 | 4.0K | 6.81 | 27K | 178K | SEC |
| 2026-07-15 | 07-17 | Bhatt Elizabeth | President and COO | S 公開市場賣出(10b5-1) | 4.0K | 33.99 | 136K | 174K | SEC |
| 2026-07-01 | 07-02 | Long Daniel D. | SVP, Drug Discovery | M 選擇權執行 | 3.3K | 2.76 | 9K | 99.7K | SEC |
| 2026-07-01 | 07-02 | Long Daniel D. | SVP, Drug Discovery | S 公開市場賣出(10b5-1) | 2.1K | 34.10 | 72K | 97.6K | SEC |
| 2026-07-01 | 07-02 | Long Daniel D. | SVP, Drug Discovery | S 公開市場賣出(10b5-1) | 1.2K | 34.81 | 43K | 96.4K | SEC |
| 2026-06-29 | 06-30 | Shaikhly Samira | Chief People Officer | M 選擇權執行 | 2.2K | 6.81 | 15K | 3.0K | SEC |
| 2026-06-29 | 06-30 | Shaikhly Samira | Chief People Officer | S 公開市場賣出(10b5-1) | 2.2K | 35.18 | 77K | 793 | SEC |
| 2026-06-22 | 06-24 | Long Daniel D. | SVP, Drug Discovery | M 選擇權執行 | 4.5K | 11.70 | 52K | 111K | SEC |
| 2026-06-22 | 06-24 | Long Daniel D. | SVP, Drug Discovery | S 公開市場賣出(10b5-1) | 8.0K | 35.10 | 281K | 103K | SEC |
| 2026-06-22 | 06-24 | Long Daniel D. | SVP, Drug Discovery | S 公開市場賣出(10b5-1) | 7.0K | 35.97 | 252K | 96.4K | SEC |
| 2026-06-22 | 06-24 | Long Daniel D. | SVP, Drug Discovery | M 選擇權執行 | 10.5K | 2.76 | 29K | 107K | SEC |
| 2026-06-12 | 06-16 | Shaikhly Samira | Chief People Officer | M 選擇權執行 | 6.3K | 11.70 | 73K | 7.0K | SEC |
| 2026-06-12 | 06-16 | Shaikhly Samira | Chief People Officer | S 公開市場賣出(10b5-1) | 6.3K | 35.08 | 219K | 793 | SEC |
| 2026-06-01 | 06-03 | Shaikhly Samira | Chief People Officer | M 選擇權執行 | 4.4K | 1.55 | 7K | 5.1K | SEC |
| 2026-06-01 | 06-03 | Shaikhly Samira | Chief People Officer | M 選擇權執行 | 943 | 2.76 | 3K | 6.1K | SEC |
| 2026-06-01 | 06-03 | Shaikhly Samira | Chief People Officer | M 選擇權執行 | 637 | 2.76 | 2K | 6.7K | SEC |
| 2026-06-01 | 06-03 | Shaikhly Samira | Chief People Officer | S 公開市場賣出(10b5-1) | 1.7K | 27.78 | 47K | 5.0K | SEC |
| 2026-06-01 | 06-03 | Shaikhly Samira | Chief People Officer | S 公開市場賣出(10b5-1) | 1.3K | 28.79 | 39K | 3.7K | SEC |
| 2026-06-01 | 06-03 | Shaikhly Samira | Chief People Officer | S 公開市場賣出(10b5-1) | 2.9K | 29.66 | 86K | 793 | SEC |
| 2026-05-26 | 05-28 | Shaikhly Samira | Chief People Officer | M 選擇權執行 | 11.8K | 6.81 | 80K | 12.6K | SEC |
| 2026-05-26 | 05-28 | Shaikhly Samira | Chief People Officer | S 公開市場賣出(10b5-1) | 11.8K | 30.06 | 355K | 793 | SEC |
| 2026-04-15 | 04-17 | Bhatt Elizabeth | President and COO | S 公開市場賣出(10b5-1) | 326 | 25.86 | 8K | 174K | SEC |
| 2026-04-15 | 04-17 | Bhatt Elizabeth | President and COO | M 選擇權執行 | 4.0K | 6.81 | 27K | 178K | SEC |
| 2026-04-15 | 04-17 | Bhatt Elizabeth | President and COO | S 公開市場賣出(10b5-1) | 2.6K | 23.76 | 61K | 176K | SEC |
| 2026-04-15 | 04-17 | Bhatt Elizabeth | President and COO | S 公開市場賣出(10b5-1) | 1.1K | 25.24 | 28K | 175K | SEC |
| 2026-03-02 | 03-04 | Shaikhly Samira | Chief People Officer | M 選擇權執行 | 53.7K | 1.55 | 83K | 54.5K | SEC |
| 2026-03-02 | 03-04 | Shaikhly Samira | Chief People Officer | M 選擇權執行 | 11.6K | 2.76 | 32K | 66.1K | SEC |
| 2026-03-02 | 03-04 | Shaikhly Samira | Chief People Officer | M 選擇權執行 | 5.1K | 2.76 | 14K | 71.2K | SEC |
| 2026-03-02 | 03-04 | Shaikhly Samira | Chief People Officer | S 公開市場賣出(10b5-1) | 4.1K | 27.51 | 113K | 67.2K | SEC |
| 2026-03-02 | 03-04 | Shaikhly Samira | Chief People Officer | S 公開市場賣出(10b5-1) | 66.4K | 28.14 | 1.9M | 793 | SEC |
| 2026-02-18 | 02-20 | Bhatt Elizabeth | President and COO | M 選擇權執行 | 4.0K | 6.81 | 27K | 178K | SEC |
| 2026-02-18 | 02-20 | Bhatt Elizabeth | President and COO | S 公開市場賣出(10b5-1) | 2.2K | 28.46 | 63K | 176K | SEC |
| 2026-02-18 | 02-20 | Bhatt Elizabeth | President and COO | S 公開市場賣出(10b5-1) | 1.8K | 29.58 | 53K | 174K | SEC |
| 2025-11-10 | 11-13 | Long Daniel D. | SVP, Drug Discovery | S 公開市場賣出 | 3.5K | 18.06 | 63K | 92.9K | SEC |
| 2025-08-18 | 08-19 | Klein Uwe | SVP, Biological Sciences | M 選擇權執行 | 4.9K | 2.76 | 14K | 15.4K | SEC |
| 2025-08-18 | 08-19 | Klein Uwe | SVP, Biological Sciences | M 選擇權執行 | 7.6K | 6.81 | 52K | 23.0K | SEC |
| 2025-08-18 | 08-19 | Klein Uwe | SVP, Biological Sciences | M 選擇權執行 | 10.5K | 2.76 | 29K | 10.5K | SEC |
| 2025-04-03 | 04-04 | Finer Jeffrey | CEO and President | M 選擇權執行 | 5.0K | 2.76 | 14K | 827K | SEC |
| 2025-04-02 | 04-04 | Finer Jeffrey | CEO and President | M 選擇權執行 | 50.0K | 2.76 | 138K | 822K | SEC |
| 2025-03-07 | 03-10 | Ezekowitz Alan | Director | P 公開市場買進 | 13.3K | 6.93 | 92K | 117K | SEC |
| 2025-03-06 | 03-06 | Ezekowitz Alan | Director | P 公開市場買進 | 41.4K | 6.00 | 248K | 104K | SEC |
| 2025-03-05 | 03-06 | Ezekowitz Alan | Director | P 公開市場買進 | 37.8K | 5.82 | 220K | 62.7K | SEC |
| 2025-03-04 | 03-06 | Ezekowitz Alan | Director | P 公開市場買進 | 7.5K | 6.35 | 48K | 24.9K | SEC |
| 2025-02-27 | 02-27 | Labrucherie Gil M | Chief Financial Officer | P 公開市場買進 | 3.7K | 5.85 | 22K | 40.0K | SEC |
| 2025-02-27 | 02-27 | Finer Jeffrey | CEO and President | P 公開市場買進 | 3.0K | 5.80 | 17K | 772K | SEC |
| 2025-02-26 | 02-27 | Finer Jeffrey | CEO and President | P 公開市場買進 | 4.0K | 5.70 | 23K | 769K | SEC |
| 2025-02-25 | 02-27 | Labrucherie Gil M | Chief Financial Officer | P 公開市場買進 | 6.3K | 5.59 | 35K | 36.3K | SEC |
| 2025-02-25 | 02-27 | Finer Jeffrey | CEO and President | P 公開市場買進 | 10.0K | 5.68 | 57K | 765K | SEC |
| 2025-02-24 | 02-26 | Third Rock Ventures VI, L.P. | TenPercentOwner | P 公開市場買進 | 18.9K | 6.00 | 113K | 4.2M | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 7.0M | 234M | 不變 | 持平 |
| TRV GP V, LLC | 6.2M | 208M | 不變 | 持平 |
| Driehaus Capital Management LLC | 4.4M | 148M | +37.5K (+1%) | 加碼 |
| TRV GP VI, LLC | 4.2M | 141M | 不變 | 持平 |
| SAMSARA BIOCAPITAL, LLC | 3.1M | 105M | 不變 | 持平 |
| GOLDMAN SACHS GROUP INC | 3.1M | 103M | +156K (+5%) | 加碼 |
| BlackRock, Inc. | 1.9M | 64.7M | +110K (+6%) | 加碼 |
| Siren, L.L.C. | 1.9M | 63.6M | −100K (-5%) | 減碼 |
| Avoro Capital Advisors LLC | 1.3M | 44.8M | 不變 | 持平 |
| Jupiter Topco LLC | 1.3M | 43.7M | 新進 | 新進 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.2M | 40.9M | +24.7K (+2%) | 加碼 |
| PRIMECAP MANAGEMENT CO/CA/ | 1.2M | 39.1M | +119K (+11%) | 加碼 |
| First Light Asset Management, LLC | 963K | 32.3M | +230K (+31%) | 加碼 |
| ADAR1 Capital Management, LLC | 941K | 31.5M | −149K (-14%) | 減碼 |
| GEODE CAPITAL MANAGEMENT, LLC | 679K | 22.8M | +34.0K (+5%) | 加碼 |
| STATE STREET CORP | 653K | 21.9M | +21.2K (+3%) | 加碼 |
| LOOMIS SAYLES & CO L P | 625K | 20.9M | 新進 | 新進 |
| Casdin Capital, LLC | 553K | 18.5M | 不變 | 持平 |
| Catalio Capital Management, LP | 536K | 18.0M | +242K (+82%) | 加碼 |
| ALGERT GLOBAL LLC | 397K | 13.3M | +376K (+1790%) | 加碼 |
| Kalehua Capital Management LLC | 389K | 13.0M | 不變 | 持平 |
| Balyasny Asset Management L.P. | 350K | 11.7M | +114K (+48%) | 加碼 |
| Longaeva Partners L.P. | 298K | 10.0M | +224K (+300%) | 加碼 |
| Soleus Capital Management, L.P. | 275K | 9.2M | 不變 | 持平 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 230K | 7.7M | +35.1K (+18%) | 加碼 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 154 +30 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 48 / 18 / 45 / 28 |
| 機構合計持股 · 佔流通股 | 47.4M · 100.0% |
| 合計季末市值 | 1.6B |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 2.7M |
|---|---|
| 與上期比 | -5.4% |
| 佔流通股數 | 5.82% |
| 日均成交量 | 355K |
| 回補天數 | 7.7 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 2.7M | -5.4% | 5.82% | 355K | 7.7 |
| 2026-08-14 | 2.9M | -18.1% | 6.16% | 568K | 5.1 |
| 2026-07-31 | 3.5M | +4.7% | 7.52% | 248K | 14.2 |
| 2026-07-15 | 3.4M | +6.2% | 7.18% | 586K | 5.7 |
| 2026-06-30 | 3.2M | +18.3% | 6.76% | 598K | 5.3 |
| 2026-06-15 | 2.7M | +1.8% | 5.71% | 343K | 7.8 |
| 2026-05-29 | 2.6M | +9.5% | 5.61% | 275K | 9.5 |
| 2026-05-15 | 2.4M | +15.6% | 5.12% | 322K | 7.4 |
| 2026-04-30 | 2.1M | -15.9% | 4.43% | 380K | 5.4 |
| 2026-04-15 | 2.5M | +12.9% | 5.26% | 305K | 8.1 |
| 2026-03-31 | 2.2M | +4.8% | 4.66% | 249K | 8.7 |
| 2026-03-13 | 2.1M | +12.3% | 4.45% | 333K | 6.3 |
| 2026-02-27 | 1.8M | +3.9% | 3.96% | 330K | 5.6 |
| 2026-02-13 | 1.8M | -7.6% | 3.81% | 281K | 6.3 |
| 2026-01-30 | 1.9M | -0.8% | 4.12% | 251K | 7.7 |
| 2026-01-15 | 1.9M | +36.0% | 4.16% | 319K | 6.1 |
| 2025-12-31 | 1.4M | +11.7% | 3.06% | 258K | 5.5 |
| 2025-12-15 | 1.3M | -13.5% | 2.74% | 274K | 4.7 |
| 2025-11-28 | 1.5M | -23.1% | 3.17% | 405K | 3.7 |
| 2025-11-14 | 1.9M | -5.1% | 4.12% | 352K | 5.5 |
| 2025-10-31 | 2.0M | -21.2% | 4.34% | 263K | 7.7 |
| 2025-10-15 | 2.6M | -16.4% | 5.51% | 443K | 5.8 |
| 2025-09-30 | 3.1M | -3.0% | 6.59% | 268K | 11.5 |
| 2025-09-15 | 3.2M | +2.8% | 6.79% | 257K | 12.3 |
| 2025-08-29 | 3.1M | -2.5% | 6.60% | 213K | 14.5 |
| 2025-08-15 | 3.2M | -0.4% | 6.78% | 243K | 13.0 |